A genetic counseling toolkit enabling BRCA1/2 founder/recurrent variant testing at the POC may add significant value, especially when incorporating the assessment of critical co-morbidities impacting on cancer risk and the option for NGS in eligible BRCA1/2 founder variant-negative cases. Here, BRCA1 is linked to cancer.